IL189065A - Purified enho-1 peptide and its use in the preparation of a pharmaceutical composition for treating obesity - Google Patents

Purified enho-1 peptide and its use in the preparation of a pharmaceutical composition for treating obesity

Info

Publication number
IL189065A
IL189065A IL189065A IL18906508A IL189065A IL 189065 A IL189065 A IL 189065A IL 189065 A IL189065 A IL 189065A IL 18906508 A IL18906508 A IL 18906508A IL 189065 A IL189065 A IL 189065A
Authority
IL
Israel
Prior art keywords
enhol
mice
peptide
ser
pro
Prior art date
Application number
IL189065A
Other languages
English (en)
Other versions
IL189065A0 (en
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of IL189065A0 publication Critical patent/IL189065A0/en
Publication of IL189065A publication Critical patent/IL189065A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
IL189065A 2005-08-05 2008-01-28 Purified enho-1 peptide and its use in the preparation of a pharmaceutical composition for treating obesity IL189065A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70594005P 2005-08-05 2005-08-05
PCT/US2006/030686 WO2007019426A2 (en) 2005-08-05 2006-08-07 A novel peptide involved in energy homeostasis

Publications (2)

Publication Number Publication Date
IL189065A0 IL189065A0 (en) 2008-08-07
IL189065A true IL189065A (en) 2012-10-31

Family

ID=37727967

Family Applications (2)

Application Number Title Priority Date Filing Date
IL189065A IL189065A (en) 2005-08-05 2008-01-28 Purified enho-1 peptide and its use in the preparation of a pharmaceutical composition for treating obesity
IL207764A IL207764A0 (en) 2005-08-05 2010-08-24 Antibody to a purified enho1 peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL207764A IL207764A0 (en) 2005-08-05 2010-08-24 Antibody to a purified enho1 peptide

Country Status (10)

Country Link
US (4) US20090253619A1 (enExample)
EP (1) EP1928487A4 (enExample)
JP (1) JP2009502208A (enExample)
KR (1) KR101004662B1 (enExample)
CN (1) CN101505786A (enExample)
AU (2) AU2006278406B2 (enExample)
CA (1) CA2618047C (enExample)
IL (2) IL189065A (enExample)
RU (2) RU2409590C2 (enExample)
WO (1) WO2007019426A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US11246912B2 (en) * 2017-08-30 2022-02-15 Hadasit Medical Research Services & Development Ltd. Methods for treating and diagnosing metastatic liver cancer
US11969460B2 (en) * 2018-06-08 2024-04-30 Saint Louis University Methods and compositions for treating decreased cognitive ability
CN110028570A (zh) * 2018-10-31 2019-07-19 华中科技大学 一种肌肉素的表达方法及其在代谢疾病中的应用
WO2024263938A2 (en) * 2023-06-23 2024-12-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Using enho gene therapy to treat cardiometabolic disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078345C1 (ru) * 1992-04-03 1997-04-27 Аникеева Светлана Петровна Способ получения сывороточного белкового препарата, влияющего на активность окислительно-энергетического обмена
US20030096951A1 (en) * 1998-08-14 2003-05-22 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
WO2000009552A1 (en) * 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Also Published As

Publication number Publication date
AU2006278406A1 (en) 2007-02-15
CA2618047C (en) 2015-04-14
US20160102126A1 (en) 2016-04-14
WO2007019426A2 (en) 2007-02-15
RU2010119559A (ru) 2011-11-20
AU2010202600A1 (en) 2010-07-15
US20130231280A1 (en) 2013-09-05
EP1928487A4 (en) 2009-11-04
US8518892B2 (en) 2013-08-27
CA2618047A1 (en) 2007-02-15
AU2006278406B2 (en) 2010-03-25
WO2007019426A3 (en) 2009-04-23
CN101505786A (zh) 2009-08-12
IL189065A0 (en) 2008-08-07
IL207764A0 (en) 2010-12-30
KR20080042866A (ko) 2008-05-15
RU2008108509A (ru) 2009-09-10
AU2010202600B2 (en) 2012-07-19
US20090253619A1 (en) 2009-10-08
KR101004662B1 (ko) 2011-01-03
JP2009502208A (ja) 2009-01-29
US20100299769A1 (en) 2010-11-25
RU2409590C2 (ru) 2011-01-20
EP1928487A2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
Münzberg et al. Leptin receptor action and mechanisms of leptin resistance
US20160102126A1 (en) Novel Peptides Involved in Energy Homeostasis
Wang et al. Low-density lipoprotein receptor-related protein 6 regulates cardiomyocyte-derived paracrine signaling to ameliorate cardiac fibrosis
US8101564B2 (en) Methods for regulating osteoclast differentiation and bone resorption using LRRc17
DK2440233T3 (en) SorCS1-like means for use in the treatment of insulin resistance and diseases associated therewith
US6689938B2 (en) Method for treatment of insulin resistance in obesity and diabetes
EP1701978B1 (en) Use of soluble T-Cadherin for the treatment of metabolic disorders
US20240342244A1 (en) Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease
HK1135608A (en) A novel peptide involved in energy homeostasis
JPWO2005097171A1 (ja) 抗肥満薬
Ohkubo Recent progress in avian leptin research
Siracusano et al. THE ROLE OF SEPSIS AND ADIPOSE TISSUE DYSFUNCTION IN SEPSIS
Ono et al. sererer denser kkk kkkk
Siracusano et al. Sepsis and Adiponectin
Patel A role for CEACAM2 in insulin homeostasis and action
WO2007115726A2 (en) The homeobox transcription factor bsx and uses thereof for treating diseases, in particular obesity

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees